Ramy Mahmoud - OptiNose President COO

OPTN Stock  USD 1.46  0.02  1.35%   

President

Dr. Ramy A. Mahmoud, M.D. serves as President, Chief Operating Officer the Company. Prior to joining us, Dr. Mahmoud spent 14 years at Johnson Johnson, where he served as Chief Medical Officer and a member of the Global Management Board of the Ethicon group of companies. During his tenure at Johnson Johnson, he also held senior roles in the pharmaceutical sector. Dr. Mahmoud served for 10 years on active duty in the U.S. Army and an additional 10 years in the Army Reserves, achieving the rank of Lieutenant Colonel. During his military service, Dr. Mahmoud held various patient care, research, and academic positions, culminating in his position as the head of the Department of Epidemiology at the Walter Reed Army Institute of Research. He has published more than 50 peerreviewed papers and textbook chapters, and has served as a scientific reviewer for a number of journals and textbooks since 2010.
Age 53
Tenure 14 years
Address 1020 Stony Hill Road, Yardley, PA, United States, 19067
Phone267 364 3500
Webhttps://www.optinose.com
Mahmoud earned a Master of Healthcare Management and Policy degree from the Harvard School of Public Health and an M.D. from the University of Miami. He has earned board certification in both Public Health/Preventive Medicine and in Internal Medicine..

Ramy Mahmoud Latest Insider Activity

Tracking and analyzing the buying and selling activities of Ramy Mahmoud against OptiNose stock is an integral part of due diligence when investing in OptiNose. Ramy Mahmoud insider activity provides valuable insight into whether OptiNose is net buyers or sellers over its current business cycle. Note, OptiNose insiders must abide by specific rules, including filing SEC forms every time they buy or sell OptiNose'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

OptiNose Management Efficiency

The company has return on total asset (ROA) of (0.1129) % which means that it has lost $0.1129 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.505) %, meaning that it created substantial loss on money invested by shareholders. OptiNose's management efficiency ratios could be used to measure how well OptiNose manages its routine affairs as well as how well it operates its assets and liabilities. At this time, OptiNose's Return On Capital Employed is very stable compared to the past year. As of the 29th of March 2024, Return On Equity is likely to grow to 0.43, while Return On Assets are likely to drop (0.35). At this time, OptiNose's Total Assets are very stable compared to the past year. As of the 29th of March 2024, Other Current Assets is likely to grow to about 4.2 M, though Net Tangible Assets are likely to grow to (61.9 M).
The company currently holds 130.23 M in liabilities. OptiNose has a current ratio of 2.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist OptiNose until it has trouble settling it off, either with new capital or with free cash flow. So, OptiNose's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like OptiNose sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for OptiNose to invest in growth at high rates of return. When we think about OptiNose's use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 2 records

PRESIDENT Age

Bill AuroraNeurocrine Biosciences
N/A
DavidAlexandre GrosNeurocrine Biosciences
43
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania. Optinose operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 189 people. OptiNose (OPTN) is traded on NASDAQ Exchange in USA. It is located in 1020 Stony Hill Road, Yardley, PA, United States, 19067 and employs 132 people. OptiNose is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

OptiNose Leadership Team

Elected by the shareholders, the OptiNose's board of directors comprises two types of representatives: OptiNose inside directors who are chosen from within the company, and outside directors, selected externally and held independent of OptiNose. The board's role is to monitor OptiNose's management team and ensure that shareholders' interests are well served. OptiNose's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, OptiNose's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sandra Helton, Independent Director
Anthony Krick, Vice Officer
Ramy Mahmoud, President COO
John Messina, Sr Affairs
Jonathan Neely, Vice President - Investor Relations and Business Operations
Joshua Tamaroff, Independent Director
Joseph Scodari, Independent Chairman of the Board
Keith Goldan, CFO
Sriram Venkataraman, Independent Director
Wilhelmus Groenhuysen, Independent Director
Peter Miller, CEO, Director
Larry Pickering, Independent Vice Chairman of the Board
Michele MBA, VP CFO
Thomas Gibbs, Chief Commercial Officer
Robert ONeil, Independent Director
Paul Spence, Chief Officer
Karen Brophy, Chief Resources
William Doyle, Independent Director
Michael Esq, Chief Secretary
Victor Clavelli, Chief Officer
Per MD, CoFounder AS
Michael Marino, Chief Legal Officer and Corporate Secretary
MPH MD, CEO Director

OptiNose Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is OptiNose a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether OptiNose offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OptiNose's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Optinose Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Optinose Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for OptiNose Stock analysis

When running OptiNose's price analysis, check to measure OptiNose's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OptiNose is operating at the current time. Most of OptiNose's value examination focuses on studying past and present price action to predict the probability of OptiNose's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OptiNose's price. Additionally, you may evaluate how the addition of OptiNose to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Is OptiNose's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.32)
Revenue Per Share
0.633
Quarterly Revenue Growth
(0.05)
Return On Assets
(0.11)
Return On Equity
(10.51)
The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.